Mallinkrodt Inc., of St. Louis, and Zogenix Inc., of San Diego, said they mutually agreed to end their co-promotion agreement covering Sumavel Dosepro (sumatriptan injection), a needle-free delivery of the migraine drug.
Cancer Prevention Pharmaceuticals Inc. and Swiss specialty pharma company Tillotts Pharma AG, a wholly owned subsidiary of Tokyo-based Zeria Pharmaceutical Co. Ltd., signed a licensing agreement for European and Japanese rights to develop and commercialize CPP-1X/sulindac for the treatment of the orphan disease familial adenomatous polyposis, and other gastrointestinal conditions.
With investors still awaiting the appointment of a new CEO following Jeremy Levin’s abrupt departure in October, Teva Pharmaceutical Industries Ltd. made an unsolicited $114 million cash offer for Nupathe Inc., starting a surprise bidding war with Endo Health Solutions, which inked a deal last month to acquire the small specialty pharma firm for $105 million in up-front cash.
Scientists from Roche Pharma Early Research and Development (pRED) have developed a method to deliver large-molecule therapeutics across the blood-brain barrier with much greater efficiency.
In its attempt to “replicate the Gleevec story in other tumor types,” Blueprint Medicines Inc.’s Series B round brought in $25 million that will fund the push led by “an elite group of people who have specialized in developing selective kinase inhibitors to known or very clear genomic drivers of cancers,” said Kyle Kuvalanka, chief business officer.
AV Therapeutics Inc. decloaked in late December by merging with a public shell company. It is developing a chemotherapy candidate, capridine, that has been shown in preclinical models to have activity against prostate and colon cancer, with plans to launch Phase I trials in the second quarter of 2014.
The first formal human cardiac safety study of Firdapse (amifampridine phosphate) met its pre-specified endpoint, demonstrating no effect on heart rate or cardiac depolarization when administered at and above therapeutic levels.
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said vedolizumab, a humanized monoclonal antibody antagonizing alpha4beta7 intregrin for treating moderate and severe ulcerative colitis and Crohn’s disease, entered two new Phase III trials in Japan.
Bristol-Myers Squibb Co., of Princeton, N.J., and partner Astrazeneca plc, of London, said the FDA approved Farxiga (dapagliflozin) tablets to improve glycemic control, along with diet and exercise in adults with Type II diabetes.
RSS